CRISPR Therapeutics AG (CRSP) Net Margin (2016 - 2025)
Historic Net Margin for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to 11973.12%.
- CRISPR Therapeutics AG's Net Margin rose 23069500.0% to 11973.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 1382.5%, marking a year-over-year decrease of 12492000.0%. This contributed to the annual value of 1093.34% for FY2024, which is 10436600.0% down from last year.
- As of Q3 2025, CRISPR Therapeutics AG's Net Margin stood at 11973.12%, which was up 23069500.0% from 23380.83% recorded in Q2 2025.
- In the past 5 years, CRISPR Therapeutics AG's Net Margin ranged from a high of 84.29% in Q2 2021 and a low of 1880950.0% during Q4 2022
- In the last 5 years, CRISPR Therapeutics AG's Net Margin had a median value of 15576.33% in 2025 and averaged 130779.74%.
- Its Net Margin has fluctuated over the past 5 years, first tumbled by 2000000000bps in 2022, then soared by 2000000000bps in 2023.
- Quarter analysis of 5 years shows CRISPR Therapeutics AG's Net Margin stood at 1095.03% in 2021, then crashed by -171671bps to 1880950.0% in 2022, then skyrocketed by 100bps to 29.13% in 2023, then crashed by -860bps to 221.38% in 2024, then tumbled by -5308bps to 11973.12% in 2025.
- Its Net Margin stands at 11973.12% for Q3 2025, versus 23380.83% for Q2 2025 and 15722.08% for Q1 2025.